Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Biogen

Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday

Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial met its primary endpoint.

Benzinga

Netflix, Biogen And Other Big Gainers From Wednesday

U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session.

Benzinga

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win

Eli Lilly And Co (NYSE:LLY) - Market cap: $295 billion.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

What The Biogen Chart Reveals As Stock Rallies Hard On Alzheimer's Data

Going back to at least December 2014, Biogen Inc (NASDAQ: BIIB) has been diligently working on drugs to cure Alzheimer's disease. Both the negative and positive data revealed over the years have instigated wild price gyrations in the issue.

Benzinga

Nasdaq Surges Over 150 Points; Gold Rises 2%

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 400 points on Wednesday.

Benzinga

Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session

Gainers

Benzinga

7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%

Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimer’s drug with Japanese partner Eisai showed promising results. RBC Capital Markets On Biogen

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Dow Jumps 300 Points; Crude Oil Rises Sharply

U.S. stocks traded higher this morning, with the Dow Jones gaining around 300 points on Wednesday.

Benzinga

US Stocks Mixed; Wholesale Inventories Increase 1.3% In August

U.S. stocks traded mixed this morning, with the Dow Jones gaining around 20 points on Wednesday.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2022

Upgrades

Benzinga

Alzheimer's drug shows promise in early results of study

Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease’s progress in a late-stage study

The Independent UK

Success of experimental Alzheimer’s drug hailed as ‘historic moment’

Study shows cognition in early-stage patients on lecanemab declines by 27% less than those on placebo

The Guardian - UK

Is iPhone Demand Really Slowing Down?, Lyft Freezes Hiring, Biogen's New Drug Slows Alzheimer's Progression: Top Financial Media Stories Wednesday, Sept. 28

Bloomberg

Benzinga

Why MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket

Gainers Atlis Motor Vehicles Inc (NASDAQ: AMV) rose 211.7% to $256.00 in pre-market trading after jumping around 199% on Tuesday.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Nasdaq Futures Slip But S&P 500, Dow Futures Hold Up Ahead Of Market Open — Apple, Biogen Stocks In Focus

U.S. stocks could struggle for direction on Wednesday after the market struggled en route to a mixed close in the previous session. Volatility could be the order of the day as another batch of Fed speeches are in the pipeline.

Daily Mirror

World's first EVER drug shown to work against Alzheimer's developed by scientists

Scientists say the development of the only drug to work against Alzheimer’s is a 'historic moment' - with regulators expected to approve the groundbreaking drug by the New Year

Benzinga

Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock

Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate.

Tribune News Service

Alzheimer’s progression slowed by drug in major trial

Eisai Co. and partner Biogen Inc. said their Alzheimer’s drug significantly slowed the disease, making it the first medicine to clearly blunt progression of the most common type of dementia in a definitive, large-scale trial.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Check Out What Whales Are Doing With BIIB

A whale with a lot of money to spend has taken a noticeably bullish stance on Biogen. Looking at options history for Biogen (NASDAQ:BIIB) we detected 19 strange trades.

The Independent UK

Biogen pays $900M to settle doctor kickback allegations

Biogen has agreed to pay $900 million to resolve allegations that it violated federal law by paying kickbacks to doctors in the form of speakers and consulting fees to persuade them to prescribe its multiple sclerosis drugs

Daily Mirror

Rugby legends hail Motor Neurone Disease breakthrough that 'will bring hope to thousands'

A breakthrough in MND treatment has been described as 'remarkable’ as rugby greats Doddie Weir and Rob Burrow - both diagnosed with the condition - say there is hope for the future

Evening Standard

Tofersen: ‘Truly remarkable’ drug slows down motor neurone disease, researchers find

Researchers say improvements reported with tofersen was ‘moment of hope’ for disease

The Independent UK

‘Truly remarkable’ new drug slows motor neuron disease

Extended use of tofersen may help stabilise muscle strength and control, researchers say

The Guardian - UK

Experimental drug shows signs of slowing motor neurone disease

Biogen drug Tofersen showed promising results when taken for six months beyond previous trial

The Independent UK

‘Promising’ new drug shown to slow motor neurone disease progression

Extended use of tofersen may help stabilise muscle strength and control, researchers say.

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.